Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Siefferman

Interventional Pain Medicine New York, NY Medical Doctor

NPI 1841440617 CMS profile 265630

2 5Th Ave Ste 7, New York, NY 10011

Open in the dashboard

General payments

$29,046

522 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Siefferman of New York, NY is reported in the CMS Open Payments database as having received $29,046 across 522 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,197 131
2024 General $4,840 134
2023 General $4,303 110
2022 General $1,481 54
2021 General $1,378 51
2020 General $1,584 26
2019 General $263 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Siefferman
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jason Siefferman were reported at $15,197. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jason Siefferman Interventional Pain Medicine median Middle half National median
2019 $263 $684 $216–$2,079 $163
2020 $1,584 $382 $122–$1,109 $114
2021 $1,378 $552 $167–$1,554 $132
2022 $1,481 $605 $187–$1,924 $149
2023 $4,303 $671 $195–$1,915 $160
2024 $4,840 $684 $206–$1,837 $164
2025 $15,197 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merz Pharmaceuticals, LLC $15,059 55 payments
  2. AbbVie, Inc. $2,610 111 payments
  3. SPR Therapeutics, Inc $1,629 8 payments
  4. Boston Scientific Corporation $1,225 20 payments
  5. Lundbeck LLC $951 52 payments
  6. Allergan Inc. $715 44 payments
  7. Abbott Laboratories $615 10 payments
  8. UCB, Inc. $595 18 payments
  9. Janssen Biotech, Inc. $501 15 payments
  10. Pfizer Inc. $467 17 payments
  11. Other $4,677 172 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,050 511 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,980 8 payments
  3. Consulting Fee $880 2 payments
  4. Education $136 1 payment
Products named General payments · program years 2019–2025
  1. Xeomin musculoskeletal $14,203 38 payments
  2. SPRINT PNS System $1,629 8 payments
  3. UBRELVY $947 34 payments
  4. QULIPTA $900 38 payments
  5. Xeomin musculoskeletal $856 17 payments
  6. WaveWriter Alpha Prime 16 $722 13 payments
  7. BOTOX Botox Therapeutic $698 32 payments
  8. VYEPTI $541 36 payments
  9. BOTOX Hyperhydrosis $536 36 payments
  10. TREMFYA $501 15 payments
  11. Other $8,942 317 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

522 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record